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Objectives . The purpose of this study was to evaluate the
cost-effectiveness of a smoking cessation program initiated after
acute myocardial infarction .
Background. The value of allocating health care resources to
smoking cessation programs after myocardial infarction has not
been compared with the value of other currently accepted inter-
ventions,
Methods. A model was developed to examine the cost .
effectiveness of a recently reported smoking cessation prograin
after an acute myocardial infarction. The cost was estimated by
considering the resources necessary to implement the program,
and the effectiveness was expressed as discounted years of life
saved. Years of life saved were estimated by modeling life expect-
ancy using a single declining exponential approximation of life
expectancy based on data from published reports .
Results . The cost-effectiveness of the nurse-managed smoking
More than 25 years after the publication of the first U .S .
Surgeon General's report (1), cigarette smoking remains an
important contributor to worldwide morbidity and mortality
from coronary heart disease . Cigarette smoking is estimated
to be responsible for >100,000 deaths from coronary heart
disease each year in the United States alone (2) . Smoking
after an acute myocardial infarction is particularly hazard-
ous. Smokers who have had an acute myocardial infarction
and continue smoking have a much higher mortality rate
than do those who stop smoking (3) .
Taylor et al . (4) reported a successful smoking cessation
program for patients hospitalized with an acute myocardial
infarction that included meetings with nurses and a regular,
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cessation program was estimated to be $220/year of life saved . In
a one-way sensitivity analysis, the cost-effectiveness of the pro-
gram remained <$20,000/year of life saved if the program de-
creased the smoking rate by only 3/1,(MO smokers (baseline
assumption 26/100 smokers), or if the program cost as much as
$g,0 /smoker (baseline assumption $100). In a two-way sensitiv-
ity analysis, even if the cost of the program were as high as
$2,000/participant, the cost-effectiveness of the program would be
<310,10/year
of life saved so long as floe program helped an
additional 12 smokers quit for every 100 carolled .
Conclusions. Over a wide range of estimates of costs and
effectiveness, a nurse-managed smoking cessation program after
acute myocardial infarction is an extremely cost-effective inter-
vention . This program is more cost-effective than beta-adrenergic
antagonist therapy after myocardial infarction .
(J Am Coll Cardiol 1993,22 :1697-702)
After
1697
SMOKING CESSA FION
brief telephone follow-up after hospital discharge . However,
despite the success of this program, organized smoking
cessation programs with telephone follow-up for survivors of
acute myocardial infarction are not widely disseminated and
are not currently reimbursed by most third-party payers in
the United States . One impediment to directing resources
toward smoking cessation programs may be the perception
that these programs are not worth their costs . The purpose
of this analysis was to determine the cost-effectiveness of a
reported smoking cessation program for smokers hospital-
ized with an acute myocardial infarction and to compare it
with that of other medical therapies .
Methods
e developed a model to compare a nurse-managed
smoking cessation program with usual smoking cessation
counseling for survivors of acute myocardial infarction . The
model is represented graphically as a decision tree in Figure
1 . The benefit was expressed as the number of discounted
life-years saved as a result of the expected reduction in
mortality among patients who stopped smoking . All calcu-
lations were rounded to the nearest $10 .
Description of the smoking cessation program . As de-
scribed by Taylor et al
. (4), the program is initiated in the
hospital when a smoker becomes clinically stable after an
0735-10971)3156 .00
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Figure 1 . A decision tree of the choice to refer a smoker for a
smoking cessation program after an acute myocardial infarction .
acute myocardial infarction . A nurse trained in smoking
cessation techniques visits the patient and reviews the risks
of continued smoking and the benefits of smoking cessation .
The nurse gives the patient a manual that explains how to
identify high risk smoking situations and counsels him or her
about how to cope with the temptation to smoke . After
hospital discharge, nurses call the patients weekly for 3
weeks and then monthly for 4 months to provide support .
Probabilities. Taylor et al . (4) compared their program
with usual postmyocardial infarction care for smokers, con-
sisting of a firm, unequivocal message from doctors and
nurses to the patients to stop smoking, and reported that 71
of every 100 smokers in the intervention group stopped
smoking compared with 45 of every 100 smokers in the usual
care group, Subjects in the study were followed up for I
year, and their smoking status was verified by measurement
of expired carbon monoxide and by serum thiocyanate
levels, On the basis of that study, we assumed that the new
program would be responsible for helping an additional 26
smokers stop smoking for every 100 smokers enrolled in the
JACC Vol . 22, No . 6
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program (I person stopping for every 3 .8 smokers enrolled in
the program).
Several studies (Table 1) have observed the smoking
status of large groups of smokers (> 100 subjects) after an
acute myocardial infarction and then followed them up for
>5 years (5-10) . In these studies the 5-year mortality rate
among smokers ranged from 22% to 47% . All of the large
studies have shown a substantial reduction in mortality in
patients who quit smoking compared with that of patients
who continued smoking . Aberg et al . (5), in the largest study,
followed up 983 men <68 years of age (mean 52 .6 years) for
up to 10 .5 years after acute myocardial infarction . In that
study, smoking status was ascertained 3 months after infarc-
tion . At 5 years, the mortality rate was 16% in the quitters
and 22% in the smokers, a 27% relative difference . This
difference in mortality rates was among the lowest in the
studies reviewed and is the estimate that we used in our
baseline analysis .
Life expectancy was modeled for smokers and nonsmok-
ers using a single declining exponential curve (11) with a time
constant calculated from the 5-year mortality rates from the
study of Aberg et al . (5) . These curves fit the reported data
well for at least the 1st 8 years of the study (Fig . 2). The
modeled survival curve for the ex-smokers slightly underes-
timates the reported survival figures, whereas the modeled
survival curve for the smokers slightly overestimates sur-
vival. Discounted life expectancy was calculated for smok-
ers and ex-smokers by taking the integral under each sur-
vival curve from year i to year i + I, multiplying that by
110 .051, and summing for i = I to 50 . The resultant
calculated gain in life expectancy from smoking cessation
(life expectancy of ex-smokers minus life expectancy of
smokers) is estimated to be 1 .7 years .
Costs. The program was assumed to require approxi-
mately 3 h of nursing time per
r
Atient (4) . The cost of nursing
time was estimated to be approximately $30/h, based on
estimated prevailing salaries in the Boston area . We as-
sumed that each patient would be given a self-help manual
and other instructional material at a cost of approximately
Table 1 .
Summary of Large Observational Studies of the Effect of Smoking Cessation on Mortality After Acute Myocardial Infarction
With at Least 5 Years of Follow-Up
5-Year Mortality Rate
before M0
*First author, reference number, year of publication
. MI = myocardial infarction
.
Stud
Patients Studied (no.) Quitters Smokers
Comment
Sparrow (8), 1978 365 (269 ten, 96 women)
12% 25%
Framingham Heart Study; quitting defined as not smoking after first MI
on the biennial examination after MI
Abets (s), 1983 983 (men only)
16% 22%
Quitting defined as not smoking 3 months after MI
Dal), (10)
. 1983
498 (men only)
20% 30
Quitting defined as not smoking 2 years after first MI or unstable
angina episode
Johansson (6),19M
156 (women only)
15% 27%
Quitting defined as not smoking 3 months after MI
Perkins (7), 1985
119 (90 men, 29 women)
21% 47%
Quitting defined as not smoking at 3 months, 6 months and yearly for
up to 5 years of follow-up
Hedback (9), 1987
305 (258 men, 47 women)
169'e' 31%
Quitting not defined (smoking defined as regular smoking in the month
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Figure 2 . Comparison of survival curves after
myocardial infarction (published values from
Aberg et al . 15] and values calculated from
modeling a declining exponential approxima-
tion of life expectancy [DEALE]) for ex-
smokers (left) and smokers (right),
to
$10/patient. Therefore, the estimated cost of the program for
each patient was $100 . Our analysis did not include the cost
of setting up the program and initially training the nurses .
To be consistent with previous cost-effectiveness studies
of smoking cessation strategies (12,13), we did not include
medical costs incurred by the survivors in subsequent years .
It is proper, nevertheless, to consider the additional medical
costs incurred for routine care during the years of life gained
and, therefore, we included those costs that were incurred
subsequently in a sensitivity analysis .
We did not include indirect costs to the patients, such as
the time lost from work while participating in the program
because the initial contact occurs while the patient is hospi-
talized, and subsequent contacts are very brief. We also did
not consider the effect of smoking cessation itself on de-
creasing days missed from work as a result of illness averted .
Sensitivity analysis. Each variable was examined over a
wide range in sensitivity analyses . The effectiveness of the
program, measured as the number of additional quitters/100
smokers enrolled in the program, varied from 0 to 33
quitters/100 smokers (baseline assumption 26/100 smokers) .
Discounted life-years gained varied from 0 .1 to 5 (baseline
assumption 1 .7) . If we assume that there was no survival
benefit to the quitters after the 8 years for which Aberg et al .
(5) followed up their cohort, then the discounted life-years
saved is 0 .3 (calculated as before up to i = 8), well within the
range in the sensitivity analysis . The costs of the program
varied from $50 to $2,000/patient (baseline assumption $100) .
Annual discounted medical costs incurred by survivors
varied from $0 to $20,000 . This range encompasses a recent
estimate of $2,100 for the annual cost of medical therapy for
patients after myocardial infarction (14)
.
ASKS
Cost-effectiveness . The cost of the recently published
smoking cessation program compared with usual care for
patients who have had an acute myocardial infarction was
estimated to be $380 for each smoker who quits (the product
of the cost per participant [$100] and the number of enrollees
KRUMHOLZ ET AL .
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needed to produce an ex-smoker 13,81) . On the basis of the
preceding analysis, each person who stopped smoking after
acute myocardial infarction gained approximately 1 .7 years
compared with patients who continued to smoke . Therefore,
the incremental cost-effectiveness is estimated to be approx-
imately $220 for each adcitional year of life saved (the
quotient of the cost of the program for each ex-smoker
produced [$380] and the number of years gained by each
ex-smoker [1 .7]) .
Sensitivity analyses . The cost/year of life saved is calcu-
lated to be <$6,000 if the program helps at least I additional
smoker to quit for every 100 smokers enrolled (Table 2) . The
program has a cost-effectiveness ratio of <$20,000/year of
life saved as long as at least three additional smokers of
Table 2 . One-Way Sensitivity Analyses
Cost-Effectiveness
($/year of life saved)
Baseline 220
Effectiveness of program in decreasing smoking
(baseline 261100)
33/100 Ito
6/100 980
1/100 5180
311A8)0 19,610
Discounted life-years gained
(baseline 1 .7)
5 80
3 130
1 380
0.10 3,850
Cost of the smoking cessation program
(baseline $100)
$50
110
$1,000
2 .260
$2,000 4,520
Medical care costs incurred during years gained
(baseline $0)
$2,100
2,330
$5,000
5 .230
$10,000
10,230
1 .0
mmg od 0.9
0.8
0.7
0.6
as
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Viprt S. Two-way sensitivity analysis in which the cost and
effectiveness of the program are varied, Lines represent coordinates
that would result in a cost-effectiveness ratio of $20 .000/year of life
saved (YOLS) and $10,0001year of life sued . Coordinates that are
above and to the left represent more favorable ratios, The baseline
result is also indicated .
every 1,000 patients enrolled are able to quit . Even if the
effectiveness of the program wits estimated to be less than
the baseline analysis, the program remained extremely cost-
effective. If the discounted years gained from smoking
cessation were assumed to be as low as 0 .1, the cost-
effectiveness of the program still did not exceed $4,000/year
of life saved . Furthermore, given the baseline assumptions
for effectiveness, the cost of the program could be as much
as $8,840/participant and still remain <$20,000/year of life
saved .
The cost of the program and its effectiveness in producing
ex-smokers varied together in a two-way sensitivity analysis
(Fig . 3) . The program could cost much more than our
baseline estimate and still be relatively cost-effective, even if
the program were less effective than assumed, For instance,
even if the cost of the program were as high as $2,010
Participant, the cost-effectiveness of the program would be
<$10, year of life saved so long as it could help 12
additional smokers to quit for every 100 enrolled .
Discussion
The principal finding of our analysis is that a smoking
cessation program for survivors of an acute myocardial
infarction is an extremely cost-effective intervention, Our
baseline analysis was modeled on a recently described
nurse-managed program that increased smoking cessation
rates by 261100 smokers . We showed that this program is
much more cost-effective than the use of either boo
adrenergic antagonists after myocardial infarction in high
risk patients ($4,7 year of life saved in 1991 dollars) (15) or
coronary artery bypass grafting for left main coronary artery
sterrosis in patients with severe angina ($7,000/quality-
adjusted year of life in 1991 dollars) (16), two interventions
that are considered very cost-effective by current standards .
Sensitivity andbyUses . Although our baseline calculations
were based on a successful nurse-managed smoking cessa-
JACC Vol . 22, No . 6
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Table 3 . Comparison of Cost-Effectiveness of Interventions for
Patients With Myocardial Infarction
MI * myocardial infarction .
Lion program, our results suggest that even smoking cessa-
tion programs with much lower effectiveness and higher cost
would have a cost-effectiveness that is superior to that of
many other interventions in cardiovascular medicine (Table
3) . If the program were as effective as that described by
Taylor et al . (4), yielding a decrease in smoking of 26/100
smokers, then it could cost as much as $2,000 for each
participant and still have a cost-effectiveness ratio that is
< We that of the hospital stay in a coronary care unit for a
patient with a 201% probability of having a myocardial
infarction, a strategy that has been estimated to cost approx-
imately $60,000/year of life saved in 1991 dollars (17) . If the
program cost only $100/smoker, as in our baseline analysis,
then an increase in the quitting rate by only I person for each
169 smokers enrolled would result in a cost-effectiveness
ratio <$10,000/year of life saved .
Assumptions of the study. Throughout the analysis, when
information was equivocal, we made assumptions that
tended to bias the analysis against the intervention . For
instance, despite the likelihood that smoking cessation
would result in savings from an expected decrease in the
incidence of cancers, strokes and respiratory-related dis-
eases, we did not include this factor in the model . The
inclusion of estimates of these savings would have resulted
in an even more favorable cost-effectiveness ratio .
Our assumptions about reinfarction after smoking cessa-
tion were also conservative . The 1990 U .S . Surgeon Gener-
al's Report (2) concluded that smoking cessation after acute
myocardial infarction decreases the rate of reinfarction .
However, because not all studies have found a statistically
significant reduction in reinfarction rate, our analysis as-
sumed that smoking cessation had no effect on reinfarction
rates. The cost-effectiveness ratio of the program may be
even more favorable if it were assumed that smoking cessa-
tion prevents reinfarction .
Cost-Effectiveness
Per Year of Life
Saved ($)
Postinfarction
Smoking cessation program 231
Beta-adrenoceptor antagonist therapy
(Goldman et al . [151)
Low risk patient 27,00)
Medium risk patient 7,400
High risk patient 4,700
pwal0rction
Thrombolytic therapy (Krumholz et al . 1141)
70 years old 21,200
75 years old 22AX)
80 years old 21,601)
Coronary care unit ifineberg et al . 1171)
Probability of MI 5% 260,1100
Probability of MI 201N) 60,000
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Despite our conservative assumptions, our conclusions
emphasize that resources devoted to smoking cessation
programs after myocardial infarction are well spent . Further-
more, our analysis extends the observations from the previ-
ous reports . Other investigators have analyzed the cost-
effectiveness of physician counseling and of nicotine gum as
an adjunct to physician counseling against smoking (12,13,18) .
Those analyses reported that the cost-effectiveness of physi-
cian counseling was <$2,000/year of life saved and that nico-
tine gum as an adjunct to physician counseling was <$10,00/
year of life saved. However, neither of those analyses
considered secondary prevention after myocardial inia,.-ction .
Limitations of the study. There are some important limi-
tations to our analysis . Because no randomized trial of
smoking cessation has been published, we based our esti-
mate of the effectiveness of smoking cessation on the large
observational studies (5-10) . In those studies, the two com-
parison groups were often very different : The smokers who
quit commonly had a worse risk profile (e.g., more severe
left ventricular failure, higher peak creatine kinase enzyme
levels) than that of the smokers who continued . Therefore, it
is more likely that the observed relative reduction in mor-
tality at 5 years was the result of smoking cessation rather
than selection (5) .
The baseline estimate of the discounted survival benefit
was calculated using a single declining exponential as a
model of survival in both groups . This approach has been
validated previously as an appropriate technique in situa-
tions where mortality is dominated by a single disease
process (11) . Figure 2 shows that this fits the actual data well
for at least the 1st 8 years after myocardial infarction . This
method may overestimate the survival benefit in the long run
because there are no data to show that the survival benefit to
quitters persists over a long peiiod and, over time, the
mortality rate in both groups is likely to increase rather than
remain constant as in the single declining exponential model .
Nevertheless, discounting future life-years minimizes any
discrepancy because it gives greater weight to the earlier
years. Furthermore, the range of the sensitivity analysis for
discounted life-years saved included values below that cal-
culated, assuming that there was no survival benefit after
8 years .
We did not model a relapse rate after smoking cessation
because smoking status in the published studies was evalu-
ated early after the acute myocardial infarction and not
subsequently verified . In the study by Aberg et al . (5), for
instance, smoking cessation was assessed only 3 months
after acute infarction . Many of those patients may have
subsequently had a relapse ; thus, the relapse rate is incor-
porated into the published survival curve .
We did not model costs incurred during years gained in
the baseline analysis because previous studies of smoking
cessation have not included those costs. Those costs are
difficult to estimate because costs incurred by years gained
may be offset by savings from the prevention of costly
morbidity that is averted as a result of smoking cessation .
KRUMHOLZ ET AL .
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Large
observational
studies with careful cost accounting
would be necessary to document the effect of smoking
cessation on subsequent medical costs . Nevertheless, the
sensitivity analysis did include a wide range of costs and
showed that the program remained very cost-effective even
if annual medical costs were as high as $10,000 .
The lack of data about the benefit of smoking cessation
after acute myocardial infarction for women and older
patients made it difficult to model explicitly the effect of age
and gender on the cost-effectiveness of this intervention .
Many of our assumptions are based on studies of middle-
aged men and women . With a paucity of empiric data it is
difficult to model confidently how age would influence many
of the assumptions in this model . However, there is evidence
that older smokers do benefit from smoking cessation (19) .
In our analysis we sought to determine whether this inter-
vention would be cost-effective over a wide range of assump-
tions that would encompass reasonable estimates pertaining
to men and women of any age .
Finally, our analysis did not consider the potential benefit
of transdennal nicotine patches . Recent studies have elem-
onstrated the value of these patches in smoking cessation
programs (20,21) . However, there are no published trials of
the patch in patients after myocardial infarction . Further-
more, there are theoretic concerns about the hazards of
administering nicotine to patients after an acute myocardial
infarction . Nevertheless, if the patches are safe and effective
in this setting, our results suggest that the benefits of
increasing smoking cessation with transdermal nicotine ther-
apy could ea , ,ily outweigh its costs . Further studies of the
role of transuermal nicotine patches in this population are
needed .
Conclusions. We believe that our analysis has important
implications for the approach to the treatment of smokers
with acute myocardial infarction . Taylor et al . (4) demon-
strated that this intervention is effective after myocardial
infarction, and we showed that it is more cost-effective than
commonly accepted treatments, such as beta-adrenergic
antagonist therapy . Organized smoking cessation programs
with telephone follow-up by trained professionals should be
a part of the care for every smoker who suffers a myocardial
infarction .
We thank Stephen G . Pauker. MD for helpful discussions of the manuscript .
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